ALX Oncology

ALX Oncology

ALX Oncology is a Burlingame, California-based biotechnology company working on pre-clinical stage immuno-oncology therapies.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

February 12, 2020
ALX Oncology raises a $105,000,000 series C round from Vivo Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
ALX Oncology Series C Funding Round February 2020
105,000,000
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
December 7, 2020
FierceBiotech
The FDA granted ALX Oncology's head and neck cancer program a fast-track tag in February, but, now, it's telling the company to hold its horses. The agency placed a partial clinical hold on the program, allowing it to enroll a maximum of 50 patients across two pivotal trials while it wraps up a nonclinical safety study.
Ben Adams
December 1, 2020
FierceBiotech
A host of top-suite venture capitalist firms have helped put together a meaty series A for an immuno-oncology biotech 2.0.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.